Patents by Inventor Zhaoxiang BIAN

Zhaoxiang BIAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10973823
    Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 13, 2021
    Assignee: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Guoqing Chen, Ruihong Gong, Dajian Yang, Aiping Lyu
  • Publication number: 20190388424
    Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.
    Type: Application
    Filed: September 27, 2016
    Publication date: December 26, 2019
    Inventors: Zhaoxiang BIAN, Guoqing CHEN, Ruihong GONG, Dajian YANG, Aiping LYU
  • Patent number: 10376555
    Abstract: Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 13, 2019
    Assignee: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Tao Huang, Chengyuan Lin
  • Publication number: 20180289766
    Abstract: Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.
    Type: Application
    Filed: March 20, 2018
    Publication date: October 11, 2018
    Inventors: Zhaoxiang BIAN, Tao HUANG, Chengyuan LIN
  • Patent number: 10040740
    Abstract: The present invention relates to an atom economic procedure of preparing iodoalkanes by hydroiodination of alkenes. In particular the present method features the generation of anhydrous hydrogen iodide from atomic hydrogen and iodine in situ by using transition metal precursor and phosphine ligandcatalyst.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: August 7, 2018
    Assignees: Hong Kong Baptist University, Yunnan Minzu University
    Inventors: Zhaoxiang Bian, Baomin Fan, Chengyuan Lin, Yongyun Zhou, Jingchao Chen
  • Patent number: 9980906
    Abstract: The present invention provides a slow and controlled released liposomal gel composition for subcutaneous administration comprises insulin or exenatide as active ingredient for reduction of blood sugar level and method of preparation thereof. Said controlled released composition has high bioavailability and is demonstrated to be able to sustain release therapeutically effective concentration of drug over a period of time and without rapid release of drug after initial administration. Method of preparing the controlled released composition of the present invention comprises the following steps: mixing insulin or exenatide, lipid and aqueous dispersion medium together; then mixing with poloxamer (e.g. F127 or P123) and/or gelatin and hyaluronic acid (HA) or the like gel solution so as to form a protective layer on surface of every lipid micro vesicles or nano-vesicles for use in intramuscular, abdominal and subcutaneous administration.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 29, 2018
    Assignee: Hong Kong Baptist University
    Inventors: Zhijun Yang, Aiping Lu, Zhaoxiang Bian, Xiaoyu Chen, Blenda Chi Kwan Wong
  • Patent number: 9868716
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity,
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 16, 2018
    Assignees: HONG KONG BAPTIST UNIVERSITY, SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE
    Inventors: Hongxi Xu, Yue Lv, Wenwei Fu, Kaixian Chen, Zhaoxiang Bian, Shilin Chen, Dajian Yang, Aiping Lu, Sun Chi Albert Chan
  • Patent number: 9783519
    Abstract: This invention relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds. More particularly, it relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds comprising phenylacetophenone derivatives using oxabenzonorbornadienes with terminal alkynes.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: October 10, 2017
    Assignees: HONG KONG BAPTIST UNIVERSITY, YUNNAN MINZU UNIVERSITY
    Inventors: Zhaoxiang Bian, Chengyuan Lin, Huaixue Mu, Baomin Fan, Yongyun Zhou, Jingchao Chen, Aiping Lu, Albert Sun-Chi Chan
  • Patent number: 9775857
    Abstract: The present invention relates to chemical constituents of the hydro-alcoholic extract of root of Lasia spinosa (L.) Thwait. More particularly, it relates to the bioactive chemical composition of Lasia spinosa (L.) Thwait and its anticancer effect. The present invention has application in the treatment of human esophageal carcinoma.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: October 3, 2017
    Assignee: HONG KONG BAPTIST UNIVERSITY
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20170204022
    Abstract: The present invention relates to an atom economic procedure of preparing iodoalkanes by hydroiodination of alkenes. In particular the present method features the generation of anhydrous hydrogen iodide from atomic hydrogen and iodine in situ by using transition metal precursor and phosphine ligandcatalyst.
    Type: Application
    Filed: January 13, 2017
    Publication date: July 20, 2017
    Inventors: Zhaoxiang BIAN, Baomin FAN, Chengyuan LIN, Yongyun ZHOU, Jingchao CHEN
  • Patent number: 9655913
    Abstract: The present invention relates to the bioactive components with the anti-proliferative property. In particular, the invention relates to one flavonol compound isolated from the root of Lasia spinosa Linn. Thwait or chemically synthesized and its specific anticancer/antitumor activity. This invention has a specific application in treating human esophageal cancer.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: May 23, 2017
    Assignees: Hong Kong Baptist University, Changshu HKBU Technology Company Limited
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Jinjin Wang, Zhijun Yang, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20170035824
    Abstract: Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising Garcinia species such as Garcinia yunnanesis Hu, for its effects of anti-migration and anti-invasion against cancer and its use as an anticancer drug. The treated cancers comprise cervical cancers and esophageal cancers. The cancer treatment comprises inhibition of cancer metastasis and inhibition of autophagic flux.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 9, 2017
    Inventors: Hongxi XU, Yuanzhi LAO, Hongsheng TAN, Naihan XU, Xiaoyu WANG, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20170014438
    Abstract: The present invention relates to the bioactive components with the anti-proliferative property. In particular, the invention relates to one flavonol compound isolated from the root of Lasia spinosa Linn. Thwait or chemically synthesized and its specific anticancer/antitumor activity. This invention has a specific application in treating human esophageal cancer.
    Type: Application
    Filed: June 23, 2016
    Publication date: January 19, 2017
    Applicants: Changshu HKBU Technology Company Limited
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Jinjin Wang, Zhijun Yang, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20160375082
    Abstract: The present invention relates to chemical constituents of the hydro-alcoholic extract of root of Lasia spinosa (L.) Thwait. More particularly, it relates to the bioactive chemical composition of Lasia spinosa (L.) Thwait and its anticancer effect. The present invention has application in the treatment of human esophageal carcinoma.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20160374985
    Abstract: The present invention disclosed a compound, proanthocyanidin A1 (PA1), which is isolated from Lasia spinosa (L.) Thwait, for its effects in shortening of clolon length, reducing colonic tissue damage, suppressing colonic myeloperoxidase activity with colitis. The said compound can be used in treating inflammatory diseases and anti-cancer leading compound.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Patent number: 9526706
    Abstract: The present invention relates to a method of using trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol for treating acute pancreatitis in a subject in needs thereof. More particularly, the present invention relates to a method of using dihydro-resveratrol, its derivatives and/or chemical variants as a remedial agent. The present invention particularly relates to the amelioration of tissue injury for the management of acute pancreatitis associated pulmonary injury of a subject.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: December 27, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Siu Wai Tsang, Hongjie Zhang, Aiping Lu, Albert Sun-Chi Chan
  • Publication number: 20160367498
    Abstract: The present invention relates to a method of using trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol for treating acute pancreatitis in a subject in needs thereof. More particularly, the present invention relates to a method of using dihydro-resveratrol, its derivatives and/or chemical variants as a remedial agent. The present invention particularly relates to the amelioration of tissue injury for the management of acute pancreatitis associated pulmonary injury of a subject.
    Type: Application
    Filed: June 16, 2015
    Publication date: December 22, 2016
    Inventors: Zhaoxiang BIAN, Siu Wai TSANG, Hongjie ZHANG, Aiping LU, Albert Sun-Chi CHAN
  • Publication number: 20160368890
    Abstract: This invention relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds.
    Type: Application
    Filed: June 18, 2015
    Publication date: December 22, 2016
    Inventors: Zhaoxiang BIAN, Chengyuan LIN, Huaixue MU, Baomin FAN, Yongyun ZHOU, Jingchao CHEN, Aiping LU, Albert Sun-Chi CHAN
  • Patent number: 9408811
    Abstract: Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound of formula (I): More particularly, it relates to said anti-prostate cancer compound that can be isolated from Garcinia esculenta or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: August 9, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Hongxi Xu, Xin Li, Hong Zhang, Yuanzhi Lao, Hongsheng Tan, Xiaoyu Wang, Kaixian Chen, Zhaoxiang Bian, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Patent number: 9408828
    Abstract: The present invention provides a compound, namely (+)-3?-Angeloyloxy-4?-keto-3?,4?-dihydroseselin (Pd-Ib) derived from Bupleurum malconense as the potential anti-inflammation drug. The present invention also relates to methods of preparing the compounds and using the same for treating inflammation.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: August 9, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Quanbin Han, Aiping Lu, Linfang Huang, Shilin Chen, Dajian Yang, Hongxi Xu, Sun Chi Albert Chan